Davide Ciardiello, Medical Oncologist at Division of Gastrointestinal and Neuroendocrine Tumors at European Institute of Oncology, shared a post on LinkedIn:
“Happy to participate to the upcoming ESMO GI Annual Congress, do not miss our presentations.
1 July
Rapid Oral Presentation – Cetuximab in the continuum of care of molecularly selected metastatic colorectal cancer: The CAPRI-2 GOIM trial.
Giulia Martini
Spoiler: data are really interesting, a phase III trial to confirm this findings is ongoing (CAPRI-3 GOIM/TTD).
2 July
77P – Predictive biomarkers for cetuximab-based rechallenge in metastatic colorectal cancer: A pooled analysis of CAVE and CAVE-2 studies.
This data represent the largest dataset to support rechallenge with anti-EGFR therapies. Exploratory biomarker analysis will be presented.
125P – Refining anti-EGFR rechallenge in metastatic colorectal cancer: A real-world circulating tumor DNA-based selection approach (the REalCHALLENGE study).
Gianluca Mauri
165TiP – Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line treatment in circulating tumor DNA–selected metastatic colorectal cancer (ROMANCE trial)
Gloria Pellizzari
The ROMANCE trial will evaluete the rolevof anti-EGFR rechallenge vs Trifluridine/tipiracil+bev in “negative hyperselected” mCRC.
82P – Using imaging biomarkers to predict antiangiogenic efficacy in pretreated metastatic colorectal cancer (mCRC)
71P – Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: A pooled ctDNA analysis of three clinical trials”
Other articles about GI Oncology on OncoDaily.